▎Editor of WuXi AppTec content team

Seagen today announced that the U.

Colorectal cancer is one of the most common and serious cancers

Tucatinib is an oral, HER2-targeting tyrosine kinase inhibitor

The application for the new supplement is based on the results of a key Phase 2 clinical trial of SSHANEER

At a median tracking period of 20.

Among the cohorts of patients receiving tucatinib monotherapy (n=30), 3.

In February of this year, Seagen began the global Phase 3 randomized trial of MOUNTAINEER-03 to examine the combination of standard chemotherapy, tucatinib, and trastuzumab as a first-line therapy for HER2-positive metastatic colorectal cancer compared with the addition (or non-addition) of the EGFR inhibitor cetuximab or the VEGF inhibitor bevacizumab

"To date, no FDA-approved drug has targeted HER2 to treat metastatic colorectal cancer," said Dr.
Marjorie Green, Seagen's head of advanced development and senior vice president, "and the FDA's priority review of tucatinib and trastuzumab combination therapies supports our belief that this therapy has the potential to benefit
patients with HER2-positive metastatic colorectal cancer who have been treated.
"
”

▲If you have any business needs, please long press to scan the QR code above, or